Lykos shores up com­mer­cial team for MD­MA drug; For­mer J&J CEO Alex Gorsky finds his next gig

Lykos Ther­a­peu­tics is on a jour­ney to get the first MD­MA-as­sist­ed PTSD ther­a­py ap­proved by the FDA, and the biotech has tapped two new lead­ers to com­plete the trip.

The ad­di­tions of com­mer­cial chief Al­li­son Rosen­thal and VP of mar­ket ac­cess Coy Stout come at a piv­otal mo­ment for the Cal­i­for­nia start­up, which for years went by the name MAPS Pub­lic Ben­e­fit Cor­po­ra­tion be­fore re­brand­ing as Lykos along­side a $100 mil­lion fi­nanc­ing in Jan­u­ary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER